Cytogenetics in the management of T-cell acute lymphoblastic leukemia (T-ALL): Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH).

Cytogenetics Diagnosis Fluorescence in situ hybridization (FISH) Karyotype Prognosis T-cell acute lymphoblastic leukemia

Journal

Current research in translational medicine
ISSN: 2452-3186
Titre abrégé: Curr Res Transl Med
Pays: France
ID NLM: 101681234

Informations de publication

Date de publication:
19 Nov 2023
Historique:
received: 03 07 2023
revised: 13 11 2023
accepted: 17 11 2023
medline: 29 11 2023
pubmed: 29 11 2023
entrez: 28 11 2023
Statut: aheadofprint

Résumé

Molecular analysis is the hallmark of T-cell acute lymphoblastic leukemia (T-ALL) categorization. Several T-ALL sub-groups are well recognized based on the aberrant expression of specific transcription factors. This recently resulted in the implementation of eight provisional T-ALL entities into the novel 2022 International Consensus Classification, albeit not into the updated World Health Organization classification system. Despite this extensive molecular characterization, cytogenetic analysis remains the backbone of T-ALL diagnosis in many countries as chromosome banding analysis and fluorescence in situ hybridization are relatively inexpensive techniques to obtain results of diagnostic, prognostic and therapeutic interest. Here, we provide an overview of recurrent chromosomal abnormalities detectable in T-ALL patients and propose guidelines regarding their detection. By referring in parallel to the more general molecular classification approach, we hope to offer a diagnostic framework useful in a broad clinical genetic setting.

Identifiants

pubmed: 38016418
pii: S2452-3186(23)00055-7
doi: 10.1016/j.retram.2023.103431
pii:
doi:

Types de publication

Practice Guideline

Langues

eng

Sous-ensembles de citation

IM

Pagination

103431

Informations de copyright

Copyright © 2023. Published by Elsevier Masson SAS.

Auteurs

Jolien De Bie (J)

Center for Human Genetics, University Hospitals Leuven, Herestraat 49, Leuven 3000, Belgium.

Julie Quessada (J)

Laboratoire de Cytogénétique Hématologique, Département d'Hématologie, CHU Timone, APHM, Aix Marseille Université, Marseille 13005, France; CRCM, Inserm UMR1068, CNRS UMR7258, Aix Marseille Université U105, Institut Paoli Calmettes, Marseille 13009, France.

Giulia Tueur (G)

Laboratoire d'hématologie, Hôpital Avicenne, AP-HP, Bobigny 93000, France.

Christine Lefebvre (C)

Unité de Génétique des Hémopathies, Service d'Hématologie Biologique, CHU Grenoble Alpes, Grenoble 38000, France.

Isabelle Luquet (I)

Laboratoire d'Hématologie, CHU Toulouse (IUCT-O), Toulouse 31000, France.

Saloua Toujani (S)

Service de Cytogénétique et Biologie Cellulaire, CHU de Rennes, Rennes 35033, France.

Wendy Cuccuini (W)

Laboratoire d'Hématologie, Unité de Cytogénétique, Hôpital Saint-Louis, AP-HP, Paris 75010, France.

Marina Lafage-Pochitaloff (M)

Laboratoire de Cytogénétique Hématologique, Département d'Hématologie, CHU Timone, APHM, Aix Marseille Université, Marseille 13005, France.

Lucienne Michaux (L)

Center for Human Genetics, University Hospitals Leuven, Herestraat 49, Leuven 3000, Belgium; Katholieke Universiteit Leuven, Leuven 3000, Belgium. Electronic address: lucienne.michaux@uzleuven.be.

Classifications MeSH